A coalition that includes the American College of Radiology and the American Society for Radiation Oncology is praising a segment of President Obama’s proposed fiscal year 2014 budget recommending the exclusion of radiation therapy, advanced imaging, and therapy services from the Stark law’s in-office ancillary services (IOAS) exception.
Ureteropelvic junction (UPJ) obstruction in young children can be successfully repaired with transperitoneal laparoscopic pyeloplasty, say researchers from Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center.
Men with BPH may obtain symptomatic relief with minimally invasive prostatic artery embolization (PAE), according to results from a small, prospective study.
New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.
A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.
A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Immediate insertion of a penile prosthesis as a treatment for acute refractory ischemic priapism resolves the acute episode of ischemic penile pain and treats the inevitable erectile dysfunction, according to a recent study.
San Diego is hosting the AUA annual meeting this year, May 4-8. This Southern California city offers a great climate in which to enjoy the outdoors while also attending the year’s preeminent urology meeting.
Drugs and devices in the pipeline from AVEO Oncology; Astellas Pharma Global Development, Inc.; Nymox Pharmaceutical Corp.; TheraVida, Inc.; and Argos Therapeutics.
Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.
More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.
Shared medical appointments for kidney stone patients are more beneficial than individual appointments, according to researchers from the University of Wisconsin School of Medicine and Public Health, Madison.
Urologists share their experiences with EMR systems.
The American College of Physicians has become the latest organization to weigh in on the controversial subject of PSA screening for prostate cancer.
In this graphic, parts of the Office of the Inspector General 2013 Work Plan that might affect a urology practice are discussed.
During the upcoming #AUA2013 annual meeting, Urology Times’ editorial consultants will be interviewing urology thought leaders on a range of topics, from health policy to management of stone disease.
Active surveillance appears to be a reasonable option for older patients with small renal masses, most of which are discovered during imaging for unrelated conditions, says the author of a recent study.
Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.
Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
In a new development in the ongoing controversy regarding the use of transvaginal mesh, the American Urogynecologic Society has released a position statement against bans of surgical options such as mesh.
The gonadotropin-releasing hormone (GnRH) antagonist degarelix (Firmagon) may be associated with lower risk of a cardiovascular event or death compared to commonly prescribed luteinizing hormone-releasing hormone (LHRH) agonists, data presented at the European Association of Urology annual congress in Milan, Italy indicate.
Increased use of percutaneous nephrolithotomy (PCNL) in recent years coincides with a rising rate of complications related to the surgery, according to a published study by researchers from Henry Ford Hospital, Detroit.
Abbott has announced that the ARCHITECT AFP test, which may help physicians detect the progression of testicular cancer, received FDA approval.
Increased adoption of the practice of obtaining 10- to 12-core biopsy specimens of the prostate has resulted in increased detection of prostate cancer across the United States, a recent large study shows.
This letter is in response to an editorial by J. Brantley Thrasher, MD (“In support of AUA guidelines,” February 2013, page 7). The editorial concerned the article, “Microhematuria a poor predictor of urinary tract cancer” (February 2013, page 8).
Urologists at last month’s Joint Advocacy Conference took five leading issues to members of Congress.
Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.
Minimally invasive prostatectomy leads to a significant decrease in workplace absenteeism but is also associated with an increase in mean health plan spending, according to a recent study.
Small kidney tumors have an aggressive potential and should be treated, according to the results of a large multicenter study presented at the European Association of Urology annual congress in Milan, Italy.
Co-administration of a phosphodiesterase type-5 inhibitor and a 5-alpha-reductase inhibitor significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo plus the 5-ARI in men with lower urinary tract symptoms of BPH and enlarged prostates, researchers reported at the European Association of Urology annual congress in Milan, Italy.